# Gland Pharma (GLAND) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/gland

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹3,169.6
- Change: +0.78%
- As of: 2026-11-06
- 1D return: +0.78%
- 5D return: +2.38%
- 1M return: +2.94%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

GLAND (₹3,169.60) exhibits a strong, established uptrend across daily, weekly, and monthly timeframes, with price trading above all key moving averages and the Supertrend indicator. The trend is particularly robust on the weekly horizon (ADX 48.9) and solid on the monthly (ADX 30.94), supported by positive DI readings. However, the stock is positioned near the upper end of its recent ranges (+91.1% in the 20-day range, +97.6% in the 252-day range), suggesting limited immediate upside room before encountering resistance at ₹3,171.00 (just 0.04% above). An upward gap anomaly occurred on November 3, 2026, adding to recent momentum, while today’s formation of an active Inside Bar suggests consolidation or indecision after the surge. With annualized volatility at 31.5% and an ATR of 3.05%, the stock remains sensitive to short-term fluctuations. Key support lies at ₹3,151.70 (pivot, -0.56%), with deeper levels at ₹3,094.80 (-2.36%).

- Trend Status: Bullish across daily, weekly, and monthly horizons; price above all MAs and Supertrend.
- Range Position: Near multi-year highs (+97.6% in 252-day range); resistance at ₹3,171.00 (0.04% away).
- Momentum & Volatility: Weekly ADX 48.9 indicates strong trend conviction; annualized volatility 31.5%; ATR 3.05%.
- Pattern & Risk: Active Inside Bar signals consolidation; nearest support at ₹3,151.70 (-0.56%); max drawdown historically -26.7%.

- Inside Bar
- Outside Bar
- Doji
- Hammer
- Bearish Engulfing Reversal

### What Changed

On November 6, 2026, Gland Pharma (NSE: GLAND) is scheduled to announce its Q2 FY2026 results, marking a key earnings event for the company. This announcement places the stock in focus alongside other major Indian entities such as Hindalco, Bosch, Siemens, and Titan during the quarterly reporting season. Market commentary indicates that investor sentiment is being influenced by these broader earnings releases, with several large-cap names driving trading activity on this date.

Technically, Gland Pharma's share price stood at ₹3,169.60 on the observation date of November 6, 2026, reflecting an increase from the previous recorded price of ₹3,145.20. While daily and weekly trend indicators are not available in the current data set, the immediate price movement shows a positive shift of approximately ₹24.40. The broader market context on this day saw the Nifty index reclaim the 24,500 level, supported by easing crude oil prices and a stronger rupee, which may provide a supportive backdrop for equity performance.

- Gland Pharma is set to report Q2 FY2026 results on November 6, 2026, placing it among the key stocks in focus for the quarter.
- The stock price closed at ₹3,169.60 on November 6, 2026, up from ₹3,145.20 in the prior snapshot.
- Broader market conditions on November 6 included a Nifty close at 24,536, driven by easing crude prices and a stronger rupee.

- [Q2 Results Today Live: Hindalco, Bosch, Siemens, Aster DM, Coromandel Intl, Gland Pharma, Voltas, Nuvama Wealth, 3M India to announce Q2 results, Bharti Airtel, LIC, Titan, ONGC, M&M shares in focus](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-hindalco-ind-bosch-siemens-aster-dm-coromandel-intl-gland-pharma-voltas-nuvama-wealth-3m-india-airtel-lic-titan-mahindra-ongc-company-results-06-november-2026/article71669522.ece)
- [Q2 Results Live Updates: Hindalco, Voltas, Aster report today; Bharti Airtel, Britannia, LIC react](https://www.cnbctv18.com/market/q2-results-live-updates-titan-ongc-lic-britannia-hindalco-astral-jubilant-bharti-airtel-hexacom-sonata-bosch-fortis-voltas-share-price-liveblog-20028478.htm)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Nifty reclaims 24,500 as crude prices ease: Can the rally extend further?](https://www.cnbctv18.com/market/nifty-outlook-friday-november-6-index-reclaims-24500-as-crude-prices-ease-can-the-rally-extend-further-20028314.htm)

### Official Filings

Gland Pharma Limited has filed key disclosures regarding regulatory outcomes, governance changes, and upcoming financial reporting. On November 3, 2026, the company received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP, a product with an estimated $214 million annual US sales run rate as of August 2026. This follows an unannounced cGMP inspection at its Dundigal facility in October 2026, which resulted in four Form 483 observations characterized by the company as procedural and unrelated to data integrity. Governance updates include a change in Directors/KMP/Auditor/RTA reported on October 30, 2026. Shareholding data as of September 30, 2026, shows Promoter Group holding 45.75% and Public Shareholding at 54.25%. The Board is scheduled to meet on November 6, 2026, to approve Q2 FY27 unaudited financial results, with an investor call following immediately.

- USFDA Approval: Approved Abbreviated New Drug Application for Methylprednisolone Acetate Injectable Suspension USP (Single-Dose and Multiple-Dose Vials) on November 3, 2026; bioequivalent to Pfizer’s Depo-Medrol with ~$214 million US sales for the twelve months ending August 2026.
- Regulatory Inspection Outcome: USFDA concluded an unannounced cGMP inspection at the Dundigal facility between October 12 and October 23, 2026, issuing four Form 483 observations described as procedural, not repeated, and unrelated to data integrity.
- Governance & Ownership: Filed change in Directors/KMP/Auditor/RTA on October 30, 2026; shareholding pattern as of September 30, 2026, indicates Promoter Group holds 45.75% and Public holds 54.25%.
- Financial Reporting Schedule: Board meeting scheduled for November 6, 2026, to consider Unaudited Standalone and Consolidated Financial Results for Q2 and H1 FY27; trading window reopens November 9, 2026.

- [Gland Pharma Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Gland Pharma Receives Approval for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and Multiple-Dose Vials". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLAND_03112026112512_Press_Release_03112026_Final.pdf)
- [GLAND PHARMA LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_18003_WebXMLFile_20261030_164441341.xml)
- [NAME(S)OF THE ACQUIRER AND ITS(PAC) : Mirae Asset Mutual Fund](https://nsearchives.nseindia.com/corporate/GLAND_10232026131931_53800.zip)
- [Gland Pharma Limited has informed the Exchange about Conclusion of USFDA Unannounced Inspection at Company s Formulation Facility at Dundigal, Hyderabad |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GLAND_23102026161753_USFDA_Dundigal_23102026.pdf)
- [Financial Results |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/GLAND_21102026170345_BM_Intimation_Q2_FY27.pdf)
- [Gland Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAND_21102026171117_Earnings_call_Intimation_Q2_FY27_Final.pdf)
- [GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_18003_WebXMLFile_20261021_180554997.xml)
- [Board Meeting Intimation |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_18003_WebXMLFile_20261021_180554997.xml)
- [GLAND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20261021_180913069.xml)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 45.75 | PUBLIC_VAL: 54.25 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 16-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1739563_16102026115909_WEB.xml)

### Fundamentals

Gland Pharma’s financial trajectory shows a divergence between strong underlying earnings power and recent operational margin pressure. For the full year ending March 2026, the company delivered robust growth, with sales rising to ₹6,431 crore and net profit jumping 47% to ₹1,027 crore, supported by a significant reduction in interest costs from ₹42 crore to ₹33 crore. This efficiency is reflected in improved Return on Capital Employed (ROCE), which recovered to 15% from 12% in the prior year.

However, the most recent quarter (Q1 FY2026-27) signals a near-term deceleration. While revenue grew sequentially to ₹1,800.27 crore, pre-tax profit fell to ₹434.98 crore from ₹505.80 crore in Q4 FY2025-26, indicating that expenses outpaced top-line growth. Despite this quarterly dip, the trailing twelve months (TTM) EPS remains elevated at ₹68.49, up from ₹62.35 a year ago. The balance sheet remains conservative with borrowings declining to ₹284 crore, though capital expenditure is ramping up as evidenced by CWIP increasing to ₹342 crore. Shareholding patterns show a notable shift, with promoter holding decreasing to 45.75% while FII participation rose to 10.36%.

The critical checkpoint for investors is whether the margin compression observed in Q1 FY2026-27 is a transient issue or a structural trend, particularly as the company scales its fixed asset base.

- Full-year FY2026 profitability surged: Net profit reached ₹1,027 crore (+47% YoY) and ROCE improved to 15%, driven by higher operating leverage and lower interest costs (₹33 crore vs ₹42 crore).
- Recent quarterly margin pressure: Q1 FY2026-27 pre-tax profit declined sequentially to ₹434.98 crore despite revenue growth to ₹1,800.27 crore, suggesting expense inflation outpacing sales.
- Balance sheet deleveraging: Borrowings have consistently fallen over three years (₹372 crore in Mar 2024 to ₹284 crore in Mar 2026), supporting financial stability.
- Ownership shift: Promoter stake decreased to 45.75% in Sep 2026, coinciding with increased Foreign Institutional Investor (FII) holding of 10.36%.

### FAQs

**What is the primary catalyst for Gland Pharma on November 6, 2026?**

Gland Pharma is scheduled to announce its Q2 FY2026 financial results. The Board of Directors meeting to approve these unaudited standalone and consolidated financial results is set for November 6, 2026, followed by an investor and analyst call at 18:30 Hrs (IST).

**Has Gland Pharma received any recent regulatory approvals from US regulators?**

Yes. On November 3, 2026, Gland Pharma announced that it received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Methylprednisolone Acetate Injectable Suspension USP. This includes single-dose vials (40 mg/mL and 80 mg/mL) and multiple-dose vials.

**What were the outcomes of the recent USFDA inspection at Gland's Hyderabad facility?**

An unannounced Current Good Manufacturing Practice (cGMP) inspection at Gland Pharma's Dundigal formulation facility in Hyderabad concluded between October 12 and October 23, 2026. The inspection resulted in four Form 483 observations, which the company characterizes as procedural, not repeated, and unrelated to data integrity. The company has committed to submitting corrective and preventive actions within the stipulated period.

**How has Gland Pharma's stock performed over the past year compared to its sector peers?**

Gland Pharma's stock has returned +66.9% over the last one year and +84.8% year-to-date as of November 6, 2026. This strong performance aligns with the broader Indian pharmaceutical sector, which has emerged as the best-performing equity segment in 2026, rising 27% year-to-date amid resilient domestic demand and improving US business margins.

- [Q2 Results Today Live: Hindalco, Bosch, Siemens, Aster DM, Coromandel Intl, Gland Pharma, Voltas, Nuvama Wealth, 3M India to announce Q2 results, Bharti Airtel, LIC, Titan, ONGC, M&M shares in focus](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-hindalco-ind-bosch-siemens-aster-dm-coromandel-intl-gland-pharma-voltas-nuvama-wealth-3m-india-airtel-lic-titan-mahindra-ongc-company-results-06-november-2026/article71669522.ece)
- [Q2 Results Live Updates: Hindalco, Voltas, Aster report today; Bharti Airtel, Britannia, LIC react](https://www.cnbctv18.com/market/q2-results-live-updates-titan-ongc-lic-britannia-hindalco-astral-jubilant-bharti-airtel-hexacom-sonata-bosch-fortis-voltas-share-price-liveblog-20028478.htm)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Nifty reclaims 24,500 as crude prices ease: Can the rally extend further?](https://www.cnbctv18.com/market/nifty-outlook-friday-november-6-index-reclaims-24500-as-crude-prices-ease-can-the-rally-extend-further-20028314.htm)
- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Gland Pharma Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Gland Pharma Receives Approval for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and Multiple-Dose Vials". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLAND_03112026112512_Press_Release_03112026_Final.pdf)
- [GLAND PHARMA LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_18003_WebXMLFile_20261030_164441341.xml)
- [NAME(S)OF THE ACQUIRER AND ITS(PAC) : Mirae Asset Mutual Fund](https://nsearchives.nseindia.com/corporate/GLAND_10232026131931_53800.zip)
- [Gland Pharma Limited has informed the Exchange about Conclusion of USFDA Unannounced Inspection at Company s Formulation Facility at Dundigal, Hyderabad |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/GLAND_23102026161753_USFDA_Dundigal_23102026.pdf)
- [Financial Results |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/GLAND_21102026170345_BM_Intimation_Q2_FY27.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹3,151.7
- Risk regime: Price Risk Currently Contained

### Support levels
- 3171
- 2858.1
- 2780.3875000000003

### Resistance levels
- 3202.0999999999985
- 3258.999999999999
- 3309.3999999999983

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.78% |
| return_10 | +12.13% |
| return_1m | +5.44% |
| return_1y | +66.94% |
| return_20 | +2.94% |
| return_3m | +21.52% |
| return_5 | +2.38% |
| return_6m | +74.97% |
| return_since_start | +75.11% |
| return_ytd | +84.81% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -26.74% |
| annualized_volatility | +31.47% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Gland Pharma Limited Q2 FY2026-27: Revenue up 1.9%, profit down 8.3%

Revenue from operations rose 1.9% quarter on quarter to ₹1,834 crore in Q2 FY2026-27, while profit before tax edged down 0.9% to ₹431 crore. Net profit fell 8.3% to ₹291 crore as tax expense increased to ₹140 crore. Operating cash flow was ₹603 crore, and cash and cash equivalents stood at ₹3,441 crore at 30 September 2026.

## Revenue growth and expenses

Revenue from operations increased for a fourth consecutive quarter, from ₹1,695 crore in Q3 FY2025-26 to ₹1,834 crore in Q2 FY2026-27. It was ₹1,800 crore in Q1 FY2026-27. Total income rose 2.2% quarter on quarter to ₹1,903 crore, including ₹69 crore of other income.

Expenses increased 3.2% quarter on quarter to ₹1,472 crore, faster than revenue. Cost of materials consumed was ₹641 crore, employee benefit expense ₹412 crore and depreciation, depletion and amortisation ₹115 crore.

## Profit and tax

Profit before tax was ₹431 crore, compared with ₹435 crore in Q1 FY2026-27. Tax expense rose to ₹140 crore from ₹118 crore; this comprised current tax of ₹146 crore and a deferred tax credit of ₹6 crore. Net profit consequently declined to ₹291 crore from ₹317 crore.

Basic and diluted EPS were both ₹17.62, versus basic EPS of ₹19.23 and diluted EPS of ₹19.22 in Q1. Trailing twelve-month EPS was ₹74.98. Finance costs were ₹7.14 crore, up from ₹4.36 crore in Q1.

## Cash flow and liquidity

Cash flow from operating activities was ₹603 crore in Q2 FY2026-27. Free cash flow was ₹414 crore, with investing activities using ₹188 crore. Financing activities used ₹360 crore.

Cash and cash equivalents were ₹3,441 crore at 30 September 2026, up from ₹3,359 crore at 31 March 2026 and ₹2,704 crore at 30 September 2025. Equity stood at ₹10,686 crore, compared with ₹10,358 crore at 31 March 2026.

## Receivables, inventory and borrowings

Trade receivables were ₹1,927 crore at 30 September 2026, up from ₹1,891 crore at 31 March 2026 and ₹1,565 crore at 30 September 2025. Inventories were ₹1,829 crore, compared with ₹1,744 crore at 31 March 2026. Current assets totalled ₹7,872 crore and total assets were ₹12,927 crore.

Current borrowings were ₹156 crore and non-current borrowings ₹63 crore at quarter-end.

## Key Takeaway

Q2 FY2026-27 extended Gland Pharma’s sequential revenue growth, but expenses rose faster and net profit fell 8.3% quarter on quarter. Operating cash flow remained substantial and the cash balance increased from March, while receivables and inventories also rose.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +45.75%
- FII holding: +10.36%
- DII holding: +33.21%
- Mutual fund holding: +29.52%
- Retail holding: +4.02%
- Promoter pledged: +0.00%

### Major reported shareholders

- Fosun Pharma Industrial Pte. Ltd — +45.75% (Bodies Corporate)
- Hdfc Mutual Fund - Hdfc Mid-Cap Fund — +5.60%
- Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund — +4.87%
- Sbi Large & Midcap Fund — +3.20%
- Mirae Asset Large & Midcap Fund — +2.92%
- Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund — +2.51%
- Kotak Midcap Fund — +2.42%
- Dsp Small Cap Fund — +1.57%
- Hdfc Life Insurance Company Limited — +1.51%
- Icici Prudential India Opportunities Fund — +1.41%

## Official filings

- 2026-11-07 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_07112026134958_NewspaperPublicationQ2FY27_Final.pdf)
- 2026-11-06 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_06112026162953_OutcomeBMQ2FY27_Final.pdf)
- 2026-11-06 — Earnings Presentation: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_06112026170538_InvestorPresentationQ2FY27_Final.pdf)
- 2026-11-06 — Press Release: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_06112026170413_PressReleaseQ2FY27_Final.pdf)
- 2026-11-06 — Financial Results Filing: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755216_06112026101234_WEB.xml)
- 2026-11-06 — Financial Results Filing: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755215_06112026101229_WEB.xml)
- 2026-11-06 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_06112026221702_EarningsCallRecordingQ2FY2027.pdf)
- 2026-11-06 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20261106_222105211.xml)
- 2026-11-06 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_06112026222930_PBvotingresults_05112026_Final.pdf)
- 2026-11-06 — Regulatory Filing: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1755232_06112026103942_WEB.xml)
- 2026-11-03 — Press Release: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_03112026112512_Press_Release_03112026_Final.pdf)
- 2026-10-30 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_18003_WebXMLFile_20261030_164441341.xml)
- 2026-10-23 — Regulatory Filing: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_10232026131931_53800.zip)
- 2026-10-23 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_23102026161753_USFDA_Dundigal_23102026.pdf)
- 2026-10-21 — Board Meeting Notice: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_21102026170345_BM_Intimation_Q2_FY27.pdf)
- 2026-10-21 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_21102026171117_Earnings_call_Intimation_Q2_FY27_Final.pdf)
- 2026-10-21 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_18003_WebXMLFile_20261021_180554997.xml)
- 2026-10-21 — Board Meeting Notice: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_18003_WebXMLFile_20261021_180554997.xml)
- 2026-10-21 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20261021_180913069.xml)
- 2026-10-16 — Shareholding Disclosure: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1739563_16102026115909_WEB.xml)
- 2026-10-12 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_12102026164934_Reg74_5__Q2FY27_Final.pdf)
- 2026-10-07 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_07102026144057_Post_newspaper_publication_PostalBallotDispatch.pdf)
- 2026-10-06 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_06102026124921_PB_Notice_XIngli_Wang_Final_Upload.pdf)
- 2026-10-06 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_18003_WebXMLFile_20261006_125816473.xml)
- 2026-10-01 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_01102026154317_BM_Outcome_01102026_Final.pdf)

## News and market events

- 2026-11-06 — CNBC-TV18: **Gland Pharma Q2 Results: Net profit jumps 58% on strong business execution, CDMO revenue up 31%** — Gland Pharma reported a 58.2% year-on-year increase in Q2 FY27 net profit to ₹291 crore, driven by strong business execution and a 31% growth in its contract development and manufacturing organisation (CDMO) segment. The company's total revenue rose 23.3% to ₹1,834 crore, with EBITDA margins expanding to 26.4%, while it advanced its US pipeline through four new launches and ten ANDA approvals. — [Source](https://www.cnbctv18.com/market/stocks/gland-pharma-share-price-q2-results-net-profit-jumps-58-on-strong-business-execution-cdmo-revenue-up-31-20029048.htm)
- 2026-11-06 — The Hindu: **Q2 Results Today Live: Hindalco, Bosch, Siemens, Aster DM, Coromandel Intl, Gland Pharma, Voltas, Nuvama Wealth, 3M India to announce Q2 results, Bharti Airtel, LIC, Titan, ONGC, M&M shares in focus** — The Hindu Business Line is providing live updates on the Q2 FY2026 earnings announcements for a broad range of listed Indian companies, including Hindalco, Bosch, Siemens, and Titan. The report highlights that shares of major entities such as Bharti Airtel, LIC, ONGC, and Mahindra & Mahindra are in focus during this quarterly results season. — [Source](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-hindalco-ind-bosch-siemens-aster-dm-coromandel-intl-gland-pharma-voltas-nuvama-wealth-3m-india-airtel-lic-titan-mahindra-ongc-company-results-06-november-2026/article71669522.ece)
- 2026-11-06 — CNBC-TV18: **Q2 Results Live Updates: Hindalco, Voltas, Aster report today; Bharti Airtel, Britannia, LIC react** — The market is reacting to Q2 earnings from companies that reported after hours on Thursday, including LIC, Bharti Airtel, Titan, ONGC, and Fortis Healthcare. Today's trading session features results from Hindalco, Voltas, Jubilant Foodworks, and Honasa Consumer, alongside other broader market names. These updates are expected to influence investor sentiment as the final trading day of the week concludes. — [Source](https://www.cnbctv18.com/market/q2-results-live-updates-titan-ongc-lic-britannia-hindalco-astral-jubilant-bharti-airtel-hexacom-sonata-bosch-fortis-voltas-share-price-liveblog-20028478.htm)
- 2026-11-06 — Mint: **Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list** — The Indian stock market is expected to open lower on November 6, with GIFT Nifty signaling a weak start despite the previous session's sharp rally. Several major stocks including Hindalco, Bharti Airtel, LIC, ONGC, Titan, Glenmark Pharma, and Vedant Fashions are in focus due to Q2 FY27 earnings releases and corporate developments. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- 2026-11-06 — CNBC-TV18: **Nifty reclaims 24,500 as crude prices ease: Can the rally extend further?** — The Nifty index extended its winning streak to a sixth consecutive session, closing at 24,536 as easing crude oil prices and a stronger rupee supported the rally. Analysts view the reclaiming of key moving averages as a bullish development, with near-term outlooks positive due to firm global cues and improving domestic demand expectations. — [Source](https://www.cnbctv18.com/market/nifty-outlook-friday-november-6-index-reclaims-24500-as-crude-prices-ease-can-the-rally-extend-further-20028314.htm)
- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-10-26 — The Hindu: **Stocks to watch, Oct 26: Raymond, RailTel, KEC Intl, Honasa, BL Kashyap, Lupin, Orchid Pharma, Gland Pharma among 15 stocks to remain in focus** — Markets in focus: a mix of M&A, contract wins, regulatory updates and new product launches across 15 stocks, from Ray­mond’s rebrand to Lupin’s FDA observation and Orchid Pharma’s Latin American licensing deal. — [Source](https://www.thehindubusinessline.com/markets/stocks-to-watch-oct-26-raymond-railtel-kec-intl-honasa-bl-kashyap-lupin-orchid-pharma-gland-pharma-among-15-stocks-to-remain-in-focus/article71624286.ece)
- 2026-10-24 — The Hindu: **U.S. FDA issues four observations to Gland Pharma formulation facility near Hyderabad** — FDA issues four Form 483 observations to Gland Pharma’s Dundigal facility after unannounced cGMP inspection. — [Source](https://www.thehindu.com/business/Industry/us-fda-issues-four-observations-to-gland-pharma-formulation-facility-near-hyderabad/article71616791.ece)
- 2026-10-18 — Mint: **Mutual funds’ portfolio shifts: Aditya Infotech, BSE stand out among top 10 stocks by holding value changes in September | Mint** — Mutual funds reshuffled their stock portfolios in September 2026, with notable changes in holding values and shareholding quantities across companies. Here's what these shifts reveal about fund managers’ buying and selling activity. — [Source](https://www.livemint.com/money/personal-finance/mutual-funds-portfolio-shifts-aditya-infotech-bse-stand-out-among-top-10-stocks-by-holding-value-changes-in-september-11792289243811.html)
- 2026-10-12 — BUSINESSTODAY: **HAL, BSE, Meesho, Swiggy, Infy: Stocks top 4 life insurers bought, sold in September** — HAL share price, BSE share price, Meesho share price, Swiggy share price, Infosys share price — [Source](https://www.businesstoday.in/markets/stocks/story/hal-bse-meesho-swiggy-infy-stocks-top-4-life-insurers-bought-sold-in-september-561044-2026-10-12)
- 2026-10-07 — Mint: **Raja Venkatraman recommends three stocks for 7 October** — Market expert Raja Venkatraman shares his top stock picks for 7 October. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-7-october-11791332912237.html)
- 2026-09-30 — BUSINESSTODAY: **Gland Pharma shares fall over 2% amid block deal report** — Gland Pharma, Gland Pharma shares, Gland Pharma block deal, Gland Pharma stock price, block deal, Rs 450 crore block deal, 15 lakh Gland Pharma shares, Gland Pharma floor price, pharmaceutical stocks — [Source](https://www.businesstoday.in/markets/stocks/story/gland-pharma-shares-fall-as-rs-450-crore-block-deal-today-558746-2026-09-30)
- 2026-09-30 — BUSINESSTODAY: **Block deals today: Avalon Tech founders to sell stake, Rs 450 crore worth Gland Pharma shares may change hands** — Block deal, Block deals today, Avalon Tech share price, Gland Pharma share price, Avalon Tech block deal, Glan Pharma block deal — [Source](https://www.businesstoday.in/markets/stocks/story/block-deals-today-avalon-tech-founders-to-sell-stake-rs-450-crore-worth-gland-pharma-shares-may-change-hands-558658-2026-09-30)
- 2026-09-30 — MONEYCONTROL: **Trade Spotlight: How should you trade Azad Engineering, Lloyds Metals and Energy, Gland Pharma, Indian Hotels, and others on September 30?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Azad Engineering,Knowledge Marine and Engineering Works,Lloyds Metals and Energy, Gland Pharma,Indian Hotels Company,APL Apollo Tubes — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-azad-engineering-lloyds-metals-and-energy-gland-pharma-indian-hotels-and-others-on-september-30-14041526.html)
- 2026-09-30 — BUSINESSTODAY: **GIFT Nifty down 81 points; Gland Pharma, Tata Steel, Adroit, Elevate, SAIL among top stocks in focus** — Stocks in news, Stocks in buzz, Stocks to watch, Stocks to buy, GIFT Nifty, GIFT Nifty cues, GIFT Nifty signals, GIFT Nifty today, Gland Pharma, Tata Steel, Elevate Campuses, SAIL, Power Mech Projects, ArMee Infotech, Avalon Tech, Swastika Infra, Adroit Industries, NTPC Green Energy, NLC India, Juniper Green Energy, KSB, ArisInfra Solutions, Inox Green, Ganesh Benzoplast — [Source](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-81-points-gland-pharma-tata-steel-adroit-elevate-sail-among-top-stocks-in-focus-558653-2026-09-30)
- 2026-09-29 — Mint: **Top 5 Sumeet Bagadia's breakout stocks: Gland Pharma, Astra Micro, Meesho, Westlife, Ujjivan | Target price, stop-loss** — Sumeet Bagadia believes buying in in Adani Enterprises, Adani Ports, Kotak Bank, Dr. Reddy's, Sun Pharma and Infosys turned the fall into a recovery — [Source](https://www.livemint.com/market/stock-market-news/top-5-sumeet-bagadias-breakout-stocks-gland-pharma-astra-micro-meesho-westlife-ujjivan-target-price-stoploss-11790688431501.html)
- 2026-09-17 — MONEYCONTROL: **Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo** — Bulk Deals,Entero Healthcare Solutions,Rentomojo,Karamtara Engineering,Gland Pharma — [Source](https://www.moneycontrol.com/news/business/markets/prasid-uno-family-trust-cuts-stake-by-1-7-in-entero-healthcare-chiratae-growth-fund-sells-1-25-stake-in-rentomojo-14032380.html)
- 2026-09-17 — BUSINESS: **Quick Wrap: Nifty Pharma Index rises 1.66%** — Powered by Capital Market - Live News — [Source](https://www.business-standard.com/markets/capital-market-news/quick-wrap-nifty-pharma-index-rises-1-66-126091700943_1.html)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-10 — MONEYCONTROL: **Fosun sale raises questions, but brokerages back Gland Pharma growth outlook** — Gland Pharma, Fosun, divestment, share sale, CDMO — [Source](https://www.moneycontrol.com/news/business/fosun-sale-raises-questions-but-brokerages-back-gland-pharma-growth-outlook-14027091.html)
- 2026-09-07 — BUSINESS: **Gland Pharma Ltd gains for third straight session** — Gland Pharma Ltd is quoting at Rs 2974.6, up 1.44% on the day as on 12:49 IST on the NSE. The stock is up 58.38% in last one year as compared to a 4.12% jump in NIFTY and a 21.48% jump in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/gland-pharma-ltd-gains-for-third-straight-session-126090700516_1.html)
- 2026-09-06 — FREEPRESSJOURNAL.IN: **Gland Pharma Stake Sale: Fosun Pharma Sells 4.55% For Rs 2,121 Crore, Holding Falls Below 50%** — Fosun Pharma sold a 4.55 percent stake in Gland Pharma for Rs 2,121.50 crore, reducing its holding to 47.22 percent. — [Source](https://www.freepressjournal.in/business/gland-pharma-stake-sale-fosun-pharma-sells-455-for-rs-2121-crore-holding-falls-below-50)
- 2026-09-05 — MONEYCONTROL: **Fosun Pharma sells 4.5% stake in Gland Pharma for Rs 2,121 crore** — Fosun Pharma, Gland Pharma, Fosun Pharma stake sale, Gland Pharma block deal, Gland Pharma shares, Fosun Pharma Gland Pharma stake, Gland Pharma shareholding, Kotak Mahindra Mutual Fund, Axis Mutual Fund, ICICI Prudential Mutual Fund, Gland Pharma Q1 results, Gland Pharma net profit, Gland Pharma revenue, pharma stocks, block deals, Fosun Pharmaceutical — [Source](https://www.moneycontrol.com/news/business/markets/fosun-pharma-sells-4-5-stake-in-gland-pharma-for-rs-2-121-crore-14023452.html)
- 2026-09-05 — The Hindu: **Fosun Pharma sells 4.5% stake in Gland Pharma for Rs 2,121 crore** — The transaction marks the second major stake sale by Fosun Pharma in the pharmaceutical company in a little over two years — [Source](https://www.thehindubusinessline.com/markets/stock-markets/fosun-pharma-sells-45-stake-in-gland-pharma-for-rs-2121-crore/article71433130.ece)
- 2026-09-04 — Economic Times: **Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 crore** — Fosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak, Axis, and ICICI Prudential Mutual Funds, while Gland Pharma shares closed higher at ₹2,932.40. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/gland-pharma-block-deal-fosun-pharma-divests-99-lakh-shares-worth-rs-2800-crore/articleshow/133768263.cms)

## Business profile

**Strategic vision:** Manufactures and markets complex generic injectables globally.

### Business segments
- **Sterile Injectables:** The company is active in sterile injectables, focusing on complex products including NCE-1s, First-to-File products, and 505(b)(2) filings.
- **Oncology:** Gland Pharma is active in the oncology therapeutic segment, focusing on complex injectables.
- **Ophthalmic:** Gland Pharma is active in the ophthalmic therapeutic segment, focusing on complex injectables.

### Competitive strengths
- Expertise in pharmaceutical research and development, manufacturing, and marketing of complex injectables.
- Global supply chain reaching over 60 countries, including key regulated markets.
- Capabilities in developing niche products through complex molecule synthesis and diverse delivery systems.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/gland
Markdown representation: https://faxioms.com/stocks/gland?render=md